Patents by Inventor Bernhard Fleckenstein

Bernhard Fleckenstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7968696
    Abstract: The present invention relates to viral interleukin-6 (v-IL-6), which can be obtained by recombinant expression of the DNA of human herpesvirus type 8 (HHV-8), and which may be used in diagnosis and treatment of human diseases such as kaposi sarcoma, Castleman's disease, multiple myeloma, kidney cell carcinoma, mesangial proliferative glomerulonephritis or B cell lymphoma.
    Type: Grant
    Filed: July 19, 1996
    Date of Patent: June 28, 2011
    Assignees: Behring Diagnostics GmbH, New York University
    Inventors: Bernhard Fleckenstein, Jens-Christian Albrecht, Frank Neipel, Alvin Friedman-Kien, Yao-Qi Huang
  • Patent number: 7491500
    Abstract: Purified genes encoding a cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: February 17, 2009
    Assignee: Schering Corporation
    Inventors: Rene De Waal Malefyt, Helmut Fickenscher, Bernhard Fleckenstein, Andrea Knappe
  • Patent number: 7339030
    Abstract: The invention relates to novel semaphorins which are distinguished by a particular domain structure and derivatives thereof, nucleic acids (DNA, RNA, cDNA) which code for these semaphorins, and derivatives thereof, and the use thereof. The present invention relates to semaphorins which have a novel, as yet undisclosed and unexpected domain structure and which possess a biochemical function in the immune system (immunomodulating semaphorins). The novel semaphorins are referred to as type L semaphorins (SemaL). They comprise an N-terminal signal peptide, a characteristic Sema domain and, in the C-terminal region of the protein, an immunoglobulin-like domain and a hydrophobic domain which represents a potential transmembrane domain.
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: March 4, 2008
    Inventors: Bernhard Fleckenstein, Armin Ensser
  • Publication number: 20070231264
    Abstract: Purified genes encoding a cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: June 18, 2007
    Publication date: October 4, 2007
    Applicant: Schering Corporation
    Inventors: Rene de Waal Malefyt, Helmut Fickenscher, Bernhard Fleckenstein, Andrea Knappe
  • Patent number: 7241438
    Abstract: Purified genes encoding a cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: August 10, 2004
    Date of Patent: July 10, 2007
    Assignee: Schering Corporation
    Inventors: Rene De Waal Malefyt, Helmut Fickenscher, Bernhard Fleckenstein, Andrea Knappe
  • Patent number: 7109002
    Abstract: The present invention relates to viral interleukin-6 (v-IL-6), which can be obtained by recombinant expression of the DNA of human herpesvirus type 8 (HHV-8), and which may be used in diagnosis and treatment of human diseases such as kaposi sarcoma, Castleman's disease, multiple myeloma, kidney cell carcinoma, mesangial proliferative glomerulonephritis or B cell lymphoma.
    Type: Grant
    Filed: April 21, 2004
    Date of Patent: September 19, 2006
    Assignees: New York University School of Medicine, BehringDiagnostics GmbH
    Inventors: Bernhard Fleckenstein, Jens Christian Albrecht, Frank Neipel, Alvin Friedman-Kien, Yao Qi Huang
  • Publication number: 20060029998
    Abstract: The invention relates to novel semaphorins which are distinguished by a particular domain structure and derivatives thereof, nucleic acids (DNA, RNA, cDNA) which code for these semaphorins, and derivatives thereof, and the use thereof. The present invention relates to semaphorins which have a novel, as yet undisclosed and unexpected domain structure and which possess a biochemical function in the immune system (immunomodulating semaphorins). The novel semaphorins are referred to as type L semaphorins (SemaL). They comprise an N-terminal signal peptide, a characteristic Sema domain and, in the C-terminal region of the protein, an immunoglobulin-like domain and a hydrophobic domain which represents a potential transmembrane domain.
    Type: Application
    Filed: September 3, 2004
    Publication date: February 9, 2006
    Inventors: Bernhard Fleckenstein, Armin Ensser
  • Publication number: 20050009106
    Abstract: Purified genes encoding a cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: August 10, 2004
    Publication date: January 13, 2005
    Inventors: Rene de Waal Malefyt, Helmut Fickenscher, Bernhard Fleckenstein, Andrea Knappe
  • Publication number: 20040228838
    Abstract: The present invention relates to viral interleukin-6 (v-IL-6), which can be obtained by recombinant expression of the DNA of human herpesvirus type 8 (HHV-8), and which may be used in diagnosis and treatment of human diseases such as kaposi sarcoma, Castleman's disease, multiple myeloma, kidney cell carcinoma, mesangial proliferative glomerulonephritis or B cell lymphoma.
    Type: Application
    Filed: April 21, 2004
    Publication date: November 18, 2004
    Applicants: Behring Diagnostics GmbH, New York University
    Inventors: Bernhard Fleckenstein, Jens-Christian Albrecht, Frank Neipel, Alvin Friedman-Kien, Yao Qi Huang
  • Patent number: 6797813
    Abstract: Purified genes encoding a cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using these reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: September 28, 2004
    Assignee: Schering Corporation
    Inventors: Rene de Waal Malefyt, Helmut Flickensher, Bernhard Fleckenstein, Andrea Knappe
  • Publication number: 20030073199
    Abstract: Purified genes encoding a cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: February 28, 2002
    Publication date: April 17, 2003
    Inventors: Rene de Waal Malefyt, Helmut Flickensher, Bernhard Fleckenstein, Andrea Knappe
  • Publication number: 20020054877
    Abstract: Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: July 29, 1999
    Publication date: May 9, 2002
    Inventors: ANDREA KNAPPE, HELMUT FICKENSCHER, BERNHARD FLECKENSTEIN
  • Publication number: 20020037851
    Abstract: Human semaphorin L (H-SemaL) and corresponding semaphorins in other species.
    Type: Application
    Filed: April 16, 2001
    Publication date: March 28, 2002
    Inventors: Bernhard Fleckenstein, Armin Ensser
  • Patent number: 6218140
    Abstract: An enhancer has been located in the upstream region of the major immediate early gene of human cytomegalovirus and has been isolated, which enhancer is more active than that from SV40 and has a wide host cell spectrum. Hence, it is suitable for eukaryotic expression systems wherein it can be incorporated upstream or downstream of the structural gene or of the regulation region.
    Type: Grant
    Filed: November 9, 1994
    Date of Patent: April 17, 2001
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Bernhard Fleckenstein, Walter Schaffner, Frank Weber, Karoline Dorsch-Häsler, Gerhard Jahn, Michael Boshart
  • Patent number: 6177080
    Abstract: The invention relates to polypeptides of the Kaposi sarcoma-associated herpes virus which have a part-sequence of at least 10 consecutive amino acids from the sequence Met Ser Ser Thr Gln Ile Arg Thr Glu Ile Pro Val Ala Leu Leu Ile Leu Cys Leu Cys Leu Val Ala Cys His Ala Asn Cys Pro Thr Tyr Arg Ser His Leu Gly Phe Trp Gln Glu Gly Trp Ser Gly Gln Val Tyr Gln Asp Trp Leu Gly Arg Met Asn Cys Ser Tyr Glu Asn Met Thr Ala Leu Glu Ala Val Ser Leu Asn Gly Thr Arg Leu Ala Ala Gly Ser Pro Ser Ser Glu Tyr Pro Asn Val Ser Val Ser Val Glu Asp Thr Ser Ala Ser Gly Ser Gly Glu Asp Ala Ile Asp Glu Ser Gly Ser Gly Glu Glu Glu Arg Pro Val Thr Ser His Val Thr Phe Met Thr Gln Ser Val Gln Ala Thr Thr Glu Leu Thr Asp Ala Leu Ile Ser Ala Phe Ser Gly Val Leu His Val Ser Thr Val Ile Pro Arg Asn Trp Val Asn Arg Arg Cys Val Gly Ile Lys Arg Asn Leu Thr Phe
    Type: Grant
    Filed: July 8, 1998
    Date of Patent: January 23, 2001
    Assignee: Biotest AG
    Inventors: Bernhard Fleckenstein, Jens-Christian Albrecht, Frank Neipel, Dieter Lang
  • Patent number: 6174685
    Abstract: The invention relates to the human herpesvirus type 6 protein p100 and parts thereof having its specific immunological properties. It further relates to antibodies directed to them and to the corresponding DNA sequences. They can be used in pharmaceutical or diagnostic compositions, optionally together with other HHV-6 proteins or the corresponding DNA sequences.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 16, 2001
    Assignee: Behring Diagnostics GmbH
    Inventors: Frank Neipel, Bernhard Fleckenstein
  • Patent number: 6025153
    Abstract: Selectable Herpesvirus saimiri vectors which have a selection gene inserted into a junction region of the L- and H-DNA are described. Vectors of this type are able persistently to infect human T cells and thus are suitable for the expression of foreign genes in human T cells. An additional advantage is that no infectious virus particles are produced during this.
    Type: Grant
    Filed: September 18, 1992
    Date of Patent: February 15, 2000
    Assignee: Hoechst AG
    Inventors: Bernhard Fleckenstein, Ralph Grassmann
  • Patent number: 5989867
    Abstract: Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: September 22, 1997
    Date of Patent: November 23, 1999
    Inventors: Andrea Knappe, Helmut Fickenscher, Bernhard Fleckenstein
  • Patent number: 5849522
    Abstract: An enhancer has been located in the upstream region of the major immediate early gene of human cytomegalovirus and has been isolated, which enhancer is more active than that from SV40 and has a wide host cell spectrum. Hence, it is suitable for eukaryotic expression systems wherein it can be incorporated upstream or downstream of the structural gene or of the regulation region.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 15, 1998
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Bernhard Fleckenstein, Walter Schaffner, Frank Weber, Karoline Dorsch-Hasler, Gerhard Jahn, Michael Boshart
  • Patent number: 5846733
    Abstract: The phosphorylated structural protein of molecular weight about 150 kd (pp 150) of human cytomegalovirus (HCMV) is highly immunogenic and is reliably recognised by human antisera. This protein can, after assignment and sequencing of the gene, be prepared, in whole or in immunogenic sections, by gene manipulation. Proteins of this type are suitable as reagents, for example in an ELISA, and as constituents of vaccines.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: December 8, 1998
    Assignee: Behring Diagnositcs GmbH
    Inventors: Gerhard Jahn, Birgit-Christine Scholl, Michael Broker, Michael Mach, Bernhard Fleckenstein, Bernd Traupe